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Abstract
Background: Primary spontaneous pneumothorax (PSP) or pulmonary cysts is one of the manifestations of
Birt-Hogg-Dube syndrome (BHDS) that is caused by heterozygous mutations in FLCN gene. Most of the mutations are
SNVs and small indels, and there are also approximately 10 % large intragenic deletions and duplications of the
mutations. These molecular findings are generally obtained by disparate methods including Sanger sequencing
and Multiple Ligation-dependent Probe Amplification in the clinical laboratory. In addition, as a genetically heterogeneous
disorder, PSP may be caused by mutations in multiple genes include FBN1, COL3A1, CBS, SERPINA1 and TSC1/TSC2 genes.
For differential diagnosis, these genes should also be screened which makes the diagnostic procedure more
time-consuming and labor-intensive.
Methods: Forty PSP patients were divided into 2 groups. Nineteen patients with different pathogenic mutations
of FLCN previously identified by conventional Sanger sequencing and MLPA were included in test group, 21
random PSP patients without any genetic screening were included in blinded sample group. 7 PSP genes including
FLCN, FBN1, COL3A1, CBS, SERPINA1 and TSC1/TSC2 were designed and enriched by Haloplex system, sequenced on a
Miseq platform and analyzed in the 40 patients to evaluate the performance of the targeted-NGS method.
Results: We demonstrated that the full spectrum of genes associated with pneumothorax including FLCN gene
mutations can be identified simultaneously in multiplexed sequence data. Noteworthy, by our in-house copy number
analysis of the sequence data, we could not only detect intragenic deletions, but also determine approximate deletion
junctions simultaneously.
Conclusions: NGS based Haloplex target enrichment technology is proved to be a rapid and cost-effective screening
strategy for the comprehensive molecular diagnosis of BHDS in PSP patients, as it can replace Sanger sequencing and
MLPA by simultaneously detecting exonic and intronic SNVs, small indels, large intragenic deletions and determining
deletion junctions in PSP-related genes.
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Background
Primary spontaneous pneumothorax (PSP, OMIM
#173600) is defined as the spontaneous occurrence of
pneumothorax in a healthy individual without obvious
underlying lung disease. A positive family history is
found in 11.5 % of PSP patients [1]. While some cases
can be attributed to several rare inherited monogenic
disorders caused by mutations in FBN1, COL3A1, CBS,
SERPINA1 and TSC1/TSC2 genes [2–6], a significant
proportion of PSP cases are caused by germline mutations
of FLCN gene, a causative gene of Birt-Hogg-Dube syn-
drome (BHD, OMIM #135150) [7–11].
BHD syndrome is an autosomal dominant disease char-
acterized by skin fibrofolliculomas, renal cancer, pulmon-
ary cysts and spontaneous pneumothorax [12–15]. Since
the clinical manifestations may be atypical and variable
[16, 17], BHD patients could exhibit a pneumothorax-
dominant phenotype with no or reduced penetrance of
skin or renal manifestations, the syndrome is considered
to be under-diagnosed [18–23]. FLCN mutation carriers
have been reported to have an increased lifetime risk of de-
veloping renal cell carcinoma (RCC) [24, 25], they should
be advised to take some preventive measures, largely aimed
at early recognition and treatment of RCC. Under the
circumstances, it is an imperative diagnostic approach
to perform genetic testing in PSP patients [17].
Thus far, the molecular diagnosis of BHD syndrome is
mainly based on Sanger sequencing. However, there are
different types of mutations in FLCN gene, comprised of
base pair substitutions, small indels, deletions and dupli-
cations [26–28], which make the diagnostic procedure
complicated and inefficient. Moreover, for differential diag-
nosis, patients with PSP should also be screened for muta-
tions in FBN1, COL3A1, CBS, SERPINA1 and TSC1/TSC2
genes. Together, this requires about 220 primer reactions
in Sanger sequencing, plus at least 7 probe sets in Multiple
Ligation-dependent Probe Amplification (MLPA) analysis.
Given the complicity, it is not feasible to conduct a
comprehensive mutation screening in clinical diagnostics
in PSP patients. In recent years, next generation sequen-
cing (NGS) and target enrichment techniques have been
further developed, allowing us to focus specifically on
genomic regions of interest for cheaper multiplexed se-
quencing of more cases. It has been successfully used in
diagnosis of genetically heterogeneous diseases, such as
breast cancer and congenital muscular dystrophy [29, 30].
Herein we sought to develop a NGS-based method using
Haloplex target enrichment and the MiSeq platform to
identify not only point mutations and indels but also copy
number variations (CNV) as an accurate and easier diag-
nostic tool for simultaneous mutation screening of all the
PSP-related genes. Using little input DNA, this system
promises a quicker, more affordable and efficient analysis
in diagnostic laboratories. To this end, we used Haloplex
to screen 7 genes responsible for PSP in 40 PSP patients
and aimed to evaluate its performance in identifying




Forty unrelated patients with PSP who had given written
informed consent participated in the genetic screen and
were divided into two groups.
Test group
Nineteen patients with different pathogenic mutations of
FLCN previously identified by conventional Sanger sequen-
cing and MLPA were included in test group (patients F01
to F19) [7, 8].
Blinded sample group
Twenty-one random PSP patients without any genetic
screening were included in blinded sample group (patients
F20 to F40).
Subjects were recruited from two tertiary hospitals,
Taizhou Hospital of Zhejiang Province and Nanjing Chest
Hospital. All participants in this study completed a
medical questionnaire. The presence of lung cysts was
evaluated by chest computed tomography. Medical and
surgical records were reviewed if available. Peripheral
blood samples were collected for DNA extraction and
subsequent analysis.
Statement of ethical approval
The study was approved by the Ethical Committees of
Taizhou Hospital of Zhejiang Province (TZYY-2011106)
and the Ethical Committees of Nanjing Chest Hospital
(NCH-2011062). Informed consent was obtained from
all individual participants included in the study.
DNA extraction, quantification, and quality control
Genomic DNA was extracted from peripheral blood sam-
ples of collected family members and controls using a
Qiagen DNA Mini blood Kit (Qiagen, Hilden, Germany)
according to manufacturer instruction. DNA purity and
concentration were assessed by the NanoDrop2000 spec-
trophotometer (Thermo Fisher Scientific, Florida, USA),
A260/A280 ratios of 1.8 to 2.0 were accepted. DNA frag-
mentation was assessed by agarose gel electrophoresis.
HaloPlex design, target enrichment, and next generation
sequencing
A custom Haloplex panel was designed using Agilent’s
online SureDesign tool (https://earray.chem.agilent.com/
suredesign/index.htm). In all, 78 target regions including
the whole gene sequences of FLCN, TSC1, TSC2, CBS,
COL3A1 and all coding exons, intron-exon boundaries
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including 50 intronic nucleotides and 5′ UTR (Untrans-
lated Regions), 3′ UTR of FBN1, SERPINA1 were cap-
tured for enrichment (Table 1). According to previous
reports, intragenic large deletions have been identified in
FLCN, TSC1, TSC2, CBS and COL3A1 genes [8, 31–33],
most breakpoints of the deletions locate in intronic se-
quences. In order to assess the performance of break-
point analysis using NGS system, we captured both
exonic and intronic sequences. However, large deletions
in SERPINA1 gene were rarely reported. Blyth et al.
(2008) suggested that Marfan patients with large dele-
tions in FBN1 gene have a more severe phenotype, and
barely manifest as isolated pneumothorax [34]. There-
fore, we only targeted coding exons, intron-exon bound-
aries, 5′- and 3′- UTRs of SERPINA1 and FBN1genes.
The predicted target coverage was 98.72 %. The 214 kb
target regions were captured using the Agilent HaloPlex
Target Enrichment System Kits for Illumina Sequencing
(Custom Panel Tier 1, ILM, 48 reactions; Agilent Tech-
nologies, Inc. Santa Clare, CA) following Agilent proto-
cols. In brief, 225 ng of genomic DNA was fragmented
using eight different restriction enzymes and denatured.
Hybridization was performed with a biotinylated custom
probe library and sample indexes, and then the target
DNA fragments were captured with magnetic streptavi-
din beads and circularized by ligation. The captured tar-
get libraries were amplified by PCR, quality controlled
and quantified using the BioAnalyzer 2100 (Agilent
Technologies, Inc. Santa Clare, CA). Equimolar amounts
of differentially indexed samples were pooled before
pair-ended sequencing 300 bp on the Illumina MiSeq
platform (Illumina Inc., San Diego, CA, USA) and the
mean read depth within the regions of interest was ~300
reads per base.
Bioinformatics analysis for NGS results
The authors implicated in the bioinformatics analysis had
no information on the patient data. Post-run sequencing
quality was assessed by FastQC (Babraham Bioinformatics,
Cambridge, UK). Sequence reads were aligned to the hg19
human reference genome (February 2009 assembly), and
analyzed with Agilent software Surecall v2.1.1.13 using
the default Haloplex parameters. The mutation reports
(*.vcf files) were then annotated using ANNOVAR
[35]. After removing all SNVs/indels occurring within
non-coding regions, the variations were filtered against
dbSNP137 NonFlagged, 1000 genomes and ESP 6500 da-
tabases. Rare, non-synonymous, exonic variants were sub-
jected to bioinformatics tool PolyPhen [36] and SIFT [37]
to evaluate their possible impact on protein structure and
function. To perform extensive analysis, we further an-
alyzed the intron sequences to identify potential splice
and branch-site mutations using splice prediction tool
ESEfinder [38]. If any potentially harmful mutation identi-
fied, validation was performed by Sanger sequencing.
Copy-number analysis
CNVs were identified using a depth-based method. Cover-
age statistics were generated using GATK Depth of Cover-
age tool version 3.1 [39, 40]. We normalized coverage in
each sample by dividing the average coverage of each exon
by the total number of on-target mapped reads for that
sample ðnormalized; coverage ¼ the average coverage of each exonthe total number of on−targetmapped reads for that sampleÞ .
To identify copy number variations at individual exons, we
compared the normalized coverage of each exon of testing
patients with that of controls. Coverage data and bars/plots
graph were produced using Prism 6. Exons with a nor-
malized coverage ratio below/above 0.7/1.3 of the mean
in controls were classified as heterozygously deleted/
duplicated and further analyzed by MLPA [8]. A 20-bp
interval was used for precise breakpoint determination.
Sanger sequencing
Sanger sequencing was performed to confirm all de-
tected variants. The primers Prism 3130 were designed
using the online software Primer3. The amplification re-
action mixture (50 μl) was subjected to denaturation at
95 °C for 2 min followed by 30 cycles at 94 °C for 1 min,
annealing temperature 60 °C for 1 min, 72 °C for 1 min
and by a final extension at 72 °C for 15 min. Bi-directional
sequencing was performed using BigDye Terminator v3.1
Table 1 Genomic regions targeted for PSP genes
Disease Gene name Chromosome location Capture region Size (bp) Exon Transcript
Birt–Hogg–Dube syndrome FLCN chr17:17115527–17145502 Whole gene 29976 14 NM_144997
Lymphangioleiomyomatosis TSC1 chr9:135766735–135822020 Whole gene 55286 23 NM_000368
TSC2 chr16:2095990–2138713 Whole gene 42724 42 NM_000548
Homocystinuria CBS chr21:44473301–44497053 Whole gene 23853 17 NM_000071
Ehlers-Danlos syndrome COL3A1 chr2:189839046–189877472 Whole gene 38527 51 NM_000090
Marfan syndrome FBN1 chr15:48700503–48938046 Exons 18559 66 NM_000138
α1- Antitrypsin deficiency SERPINA1 chr14:94843084–94857030 Exons 4863 7 NM_001002236
Capture size 213788 220
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Cycle Sequencing Kit, version 3.1 (Applied Biosystems,
Foster, CA, USA) and analyzed on an ABI genetic analyzer
(Applied Biosystems, Foster City, CA, USA).
Results
A total of 40 samples were included in this study. Nineteen
patients with 15 different types of FLCN pathogenic muta-
tions previously identified by conventional Sanger se-
quencing and MLPA were chosen as positive controls
to evaluate the performance of the target enrichment
method. In addition, 21 blinded samples from genetically
untested PSP patients were also examined by this method
to identify the underlying mutation(s) responsible for PSP
and to assess this method for its diagnostic potential. All
the results were re-confirmed by conventional Sanger se-
quencing and MLPA. The strategy used in this study were
detailed in Fig. 1c and Table 1.
Sequencing quality metrics
The obtained sequencing data was analyzed by FastQC
software, which indicated good-quality sequencing metrics,
with an average 80.53 % of the sequenced bases above Q30.
On average, a mean coverage of 364× was obtained per
sample (ranged 210 ×–699×) (Fig. 1a). Different average
coverage were obtained for the seven analyzed genes, ran-
ging from 243× (COL3A1) to 592× (SERPINA1) (Fig. 1b).
All genes were covered at more than 30× for at least 96 %
of the target regions, promising the CNV analysis. The per-
centage of sequencing on target was 72.35 %.
Identification of SNVs, indels and CNVs in test group:
validation of the diagnostic strategy
All 15 different pathogenic sequence changes were cor-
rectly identified in the 19 positive control samples (Table 2;
patients F01-F19), resulting in a diagnostic rate of 100 %
for the detection of pathogenic mutations in our system.
These encompassed a variety of mutations, including 2
SNVs (1 stop gain and 1 splice site mutation), 4 inser-
tions/6 deletions ranging from 1 to 23 bases and 3 large
intragenic deletions. The false-negative rate was 0 %. All
samples were analyzed blind to their mutations.
Detection of exon deletions and breakpoint analysis
We observed that the coverage varied significantly between
positions from the same sample, however, the samples cap-
tured with an identical protocol had very similar distribu-
tion of sequencing depth. In this context, we normalized
coverage of each exon for on-target mapped bases for that
sample and performed the CNV analysis using a depth-
based method. This analysis allowed us to identify 4 pa-
tients with heterozygous large intragenic deletions of FLCN
gene in our study cohort: 1 deletion in FLCN comprised
exons 1–3 (average normalized depth ratio = 0.356). One
deletion in FLCN comprised exon 14 (normalized depth
Fig. 1 Representative Quality metrics of the targeted-NGS method and strategy for mutation screening in the targeted genes. a Representation
of the average depth of each sample. The coverage depth was >200× for each sample. b Mean coverage obtained for the different genes across
patients. Bar chart displaying the mean coverage of each gene in all samples. Error bars represent standard deviation. The blue line shows the lower
limit of coverage appropriate to perform CNV analysis (30×). c Strategy for comprehensive mutation screening of the targeted genes in PSP cohort
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ratio = 0.601) and 2 deletions in FLCN comprised exons 9–
14 (average normalized depth ratio = 0.533 and 0.539,
respectively) (Fig. 2a-d).
We subsequently managed to identify exact break-
points of the deletions by calculating the normalized
depth of a set of 20 bp-interval contigs covered the en-
tire FLCN gene (Fig. 2e-h, Table 3). For patient F16, by
using MLPA, of which probes are designed in the exons
of FLCN gene, we detected a deletion of exons 1–3 [8].
The estimated deletion size is between 5346–18666 bp
in length, while with the NGS strategy, we were able to
restrict it to about 7650 bp, closed to its actual deletion
size (Fig. 2i). Likewise, in patient F17 and F18/F19, we
reduced the estimated size of deletion from 1645–8671 bp
and 5555–13782 bp down to about 1740 bp and
6117–12017 bp, respectively (Fig. 2i).
The breakpoints for four large intragenic deletions in
FLCN had been identified by genomic amplification of
the DNA regions across the deletion junctions, followed
by Sanger sequencing. Each large deletion is flanked by
Alu repeat sequences that mediate the mutation. Our
NGS system accurately identified exon deletions and de-
termined breakpoints on the targeted sequence within
about 100 bp, largely narrowed the boundaries of the de-
letions, which made it much easier to design primers for
genomic amplification of the deletion junction.
Mutation analysis in blinded sample group
Our study shown there were an average of 194 variants
per sample within the 214 kb targeted region in our
blinded PSP cohort of PSP. After removing all SNVs/
indels occurring within non-coding regions, the varia-
tions were filtered against dbSNP137 NonFlagged, 1000
genomes and ESP 6500 databases, and then submitted
to PolyPhen and SIFT to evaluate possible impact of the
variations on protein structure and function. Using this
filtering criteria, there was 0–1 novel, predicted harmful
variant remained for each sample. Of the 21 patients, we
detected clearly pathogenic mutations in 3 cases (2 in
FLCN, 1 in FBN1) and likely pathogenic mutations in
Table 2 SNVs, Indels, and exon deletions identified by the assay in Test Group
Patient ID Gene RefSeq Exon or Intron Mutation(s) by nucleotide Mutation(s) by
amino acid
Mutation type Conventional method
of detection
F01 FLCN NM_144997 exon11 c.1285dupC p.H429PfsX27 Frameshift insertion,
protein truncation
Sanger Sequence
F02 FLCN NM_144997 exon11 c.1285dupC p.H429PfsX27 Frameshift insertion,
protein truncation
Sanger Sequence
F03 FLCN NM_144997 exon14 c.1579_1580insA p.R527QfsX75 Frameshift deletion,
protein truncation
Sanger Sequence
F04 FLCN NM_144997 exon4 c.182_186dupACAGC p.P63TfsX69 Frameshift deletion,
protein truncation
Sanger Sequence
F05 FLCN NM_144997 exon12 c.1360dupT p.C454LfsX2 Frameshift deletion,
protein truncation
Sanger Sequence
F06 FLCN NM_144997 exon11 c.1285delC p.H429TfsX39 Frameshift deletion,
protein truncation
Sanger Sequence
F07 FLCN NM_144997 exon9 c.946_947delAG p.S316YfsX73 Frameshift deletion,
protein truncation
Sanger Sequence
F08 FLCN NM_144997 exon10 c.1156_1175del p.S386DfsX63 Frameshift deletion,
protein truncation
Sanger Sequence
F09 FLCN NM_144997 exon14 c.1648_1658del p.L550DfsX48 Frameshift deletion,
protein truncation
Sanger Sequence
F10 FLCN NM_144997 exon6 c.469_471delTTC p.F157del In-frame deletion Sanger Sequence
F11 FLCN NM_144997 exon13 c.1522_1524delAAG p.K508del In-frame deletion Sanger Sequence
F12 FLCN NM_144997 intron4 c.250–3_268del — Splice site Sanger Sequence
F13 FLCN NM_144997 exon6 c.507G > A p.W169X Nonsense mutation Sanger Sequence
F14 FLCN NM_144997 exon6 c.507G > A p.W169X Nonsense mutation Sanger Sequence
F15 FLCN NM_144997 intron13 c.1539–1G > A — Splice site Sanger Sequence
F16 FLCN NM_144997 exon1–3 c.-504–1355_-25 + 894 del — Large intragenic deletion MLPA
F17 FLCN NM_144997 exon14 c.1539–476_1740 + 1077 del — Large intragenic deletion MLPA
F18 FLCN NM_144997 exon9–14 c.872–562_1740 + ?a del — Large intragenic deletion MLPA
F19 FLCN NM_144997 exon9–14 c.872–562_1740 + ?a del — Large intragenic deletion MLPA
aThe breakpoint is within the 3′ flank of the FLCN gene, which was not included in the panel
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Fig. 2 Detection of copy number variants and mapping of deletion junctions. a-d Representation of the normalized depth ratio of each exon in
FLCN gene. Exons with a normalized coverage ratio below 0.7 were classified as heterozygously deleted. e-h Representation of the normalized
depth ratio of 20-bp intervals in FLCN gene. The red dotted lines represent the average ratio of the deletion area. i The upper panel shows genomic
structure of the FLCN gene (data from USCS database). The blue line represents actual deletion size. Deletion size of NGS-based and MLPA-based
methods are represented by green line and red line, respectively. The solid line represents the definite deletion size determined by each
method. Interval of vertical bars on each side of solid lines represent the range of probable deletion junctions
Table 3 Genomic deletions and breakpoints identified by the assay
Patient ID Gene Genomic
event
Breakpoint identified by NGS system Breakpoint identified by amplification
of the deletion junction
Chromosome Starta Enda Size (bp) Average
ratiob
Chromosome Start End Size (bp)
F16 FLCN Deletion exons
1–3
17 17134237 17141880 7644 0.377 17 17134286 17141828 7543
F17 FLCN Deletion exons
14
17 17115904 17117646 1743 0.534 17 17115898 17117706 1809




17123085 — 0.513 17 17115206 17123002 7747




17123085 — 0.516 17 17115206 17123002 7747
aBreakpoints are defined by the external boundaries of 20 bp-intervals. Breakpoints are flanked by Alu repeats
bAverage of normalized depth ratio of each 20 bp-interval
cThe breakpoint is within the 3′ flank of the FLCN gene, which was not included in the panel
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the other 3 cases (Table 4). All of the variants were con-
firmed by Sanger sequencing.
Two small frameshift deletions were identified in FLCN
gene in patients F29 and F37, both resulting in a truncated
protein of FLCN. And one of them, a c.1648_1658 dele-
tion in exon 14 of the FLCN gene had been detected in
patient F09. A nonsense mutation were detected in FBN1
gene in patient F32, it was a C to T transition (c.6169
C > T) in exon 51, predicting an early stop codon at
position 2057 (p.Arg2057Ter) which causes a prema-
ture termination of the protein. This mutation has not
been recorded in any database including FBN1 mutation
database [41]. In this unscreened cohort of PSP patients,
we also identified two missense mutations predicted to be
damaging by SIFT and Polyphen2. One of them was a
c.2269G >C transversion in exon 19 of the FBN1 gene,
which converted the codon GAT for Aspartic at position
757 to CAT, a codon for Histidine. This variant is pre-
dicted by ScanProsite to situate in the EGF-like
calcium-binding domain of FBN1 [42]. The other was a
c.1631G >A transition in exon 15 of the TSC1 gene, which
was predicted to substitute a polar uncharged glycine resi-
due for a negatively charged glutamic residue (p.Gly544-
Glu), presenting a distinct change in amino acid properties.
We also detected a G to A point mutation in intron 10
(c.1177–21G > A) of FLCN gene (Fig. 3a). This variant
located within the branch-site sequence, by using the ESE-
finder, we obtained a matrix score for the c.1177–21G >A
substitution (2.2919) of the branch-site sequence, rela-
tively less than a score for the wild type (2.7018) (Fig. 3b),
indicating that it may disrupt the branch-site in this gene.
However, because of unavailability of the patient’s tissue,
we were unable to verify it at transcript level.
In general, NGS method not only successfully identi-
fied missense, nonsense, splice site, intronic branch
site, small indel, and large deletion changes in positive
and blinded samples, but also determined approximate
deletion junction within about 100 bp deviation by
using a depth-based method.
Discussion
In this study, to establish a genetic diagnostic method
for PSP, we evaluated the performance of targeted en-
richment next-generation sequencing for the molecular
diagnosis of PSP patients. We enriched 7 genes which
are known to cause PSP using our self-designed Halo-
plex panel (Table 1) and sequenced them on Miseq plat-
form. In test group, our target-enrichment NGS method
successfully identified all 19 pathogenic mutations in-
cluding SNVs, Indels and large intragenic mutations pre-
viously detected by Sanger sequencing and MLPA. No
false negative result in test group was obtained. More-
over, we also detected the breakpoints of the deletions
within 100 bp using a depth-based bioinformatics
method. In blinded sample group, we detected 3 defin-
itely pathogenic mutations including a novel FBN1 mu-
tation and 3 likely pathogenic mutations including an
intronic branch-site mutation. Therefore, we conclude
that our system has a more extensive performance than
Sanger sequencing and MLPA.
As BHD patients often receive medical attention for
their pneumothorax onset in the hospital, genetic
screening in PSP patients will help early diagnose of
BHD syndrome, thus lead to early recognition and treat-
ment of renal cell carcinoma. However, for screening,
Sanger sequencing and MLPA are relatively low
throughput, inefficient and expensive. Our targeted
next-generation sequencing method successfully and ef-
ficiently identifies full spectrum of FLCN gene mutations
in a single experiment.
By using a depth-based bioinformatics method, we also
narrowed the range of breakpoints to a great extent, but
we did not identify the precise breakpoints of the dele-
tions, as it is reported that all FLCN intragenic deletions
Table 4 Mutations identified in the 21 SP patients of the blinded sample group



























Situates in the EGF-like
calcium-binding domain
of FBN1; highly conserved;
predicted damaging






F34 FLCN NM_144997 intron10 c.1177–21G > A — Splicing Heterozygous Likely
Pathogenic
Branch Site mutation
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are Alu repeats-mediated [8], yet the low sensitivity in
detecting CNVs in repeat regions is not completely
solved [43], and Sanger sequencing is still the gold
standard for breakpoint determination. Our NGS ap-
proach thus obviates the need for separate testing for
genomic deletions/duplications after Sanger sequencing,
and can also largely minimize the boundaries of the dele-
tions, which will make it much easier to design primers
for long-range PCR amplification. Our limitation is that
one of the breakpoint of exon 9–14 deletion was not re-
covered since our design did not include the 3′ flank of
FLCN gene. To optimize our method, the 5′ flank and 3′
flank sequences of tested genes should be included.
In the blinded PSP cohort, two out of twenty-one pa-
tients (9.5 %) were identified to carry pathogenic muta-
tions in FLCN gene. This is in concordance with the
previous report that up to 10 % of PSP patients are car-
rying FLCN mutations [7, 8]. A novel nonsense muta-
tion in FBN1 (c.6169C > T; p.Arg2057Ter) was found in
a male PSP patient. It was classified as definitely patho-
genic mutation and was not recorded in any database.
Our finding expand the spectrum of mutations in Marfan
syndrome. Interestingly, a novel intronic variant in FLCN
(c.1177–21G > A) was also detected by this method, bring-
ing forward the need of raising awareness of intronic
variant in pathogenesis, which is often avoided by trad-
itional Sanger sequence.
Among the targeted genes, we also identified three
mutations in FBN1 and TSC1 gene in PSP patients in
addition to FLCN gene, but no predicted harmful variant
was detected in TSC2, CBS, COL3A1 and SERPINA1
gene. Patients with mutations in these genes often ex-
press as syndromes and can be easily diagnosed. Isolated
spontaneous pneumothorax patients with mutations in
these genes are rare [44]. Nevertheless, pulmonologists
should consider these syndromes and sequence these genes
when treating patients for spontaneous pneumothorax,
since early detection improves the prognosis significantly.
Moreover, a cost analysis of NGS approach showed
significant savings. The cost with conventional Sanger
sequencing is about $1760 per sample for 220 PCR and
sequencing reactions, and the cost with 7 MLPA reac-
tions is about $110 per sample. While a total cost of
Haloplex target enrichment sequencing is about $400.
With our NGS-based assay, a 78 % of cost savings per
sample could be achieved in PSP diagnostic procedure.
Conclusions
This is the first study to evaluate the performance of
NGS in the detection of exonic and intronic SNVs,
Fig. 3 Sanger sequencing and ESEfinder results of the branch-site mutation. a Sequencing chromatograms show a heterozygous mutation
c.1177–21G > A in FLCN gene. The arrow indicates the position of the nucleotide mutation and the boxed nucleotides indicate the branch site
predicted by ESEfinder. b ESEfinder results for the c.1177–21G > A substitution and for the wild type of the branch-site sequence
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Indels and large intragenic deletions, and to develop a
cost- and time-effective screening system for the mo-
lecular diagnosis of BHDS in PSP cohort. In conclusion,
NGS based Haloplex target enrichment technology is a
rapid, high-throughput and cost-effective screening
strategy for the molecular diagnosis of BHD in PSP pa-
tients, as it can replace Sanger sequencing and MLPA by
simultaneously detecting exonic and intronic SNVs,
small indels, large intragenic deletions and determining
deletion junctions in PSP-related genes.
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